Health behavior outcomes in stroke survivors prescribed wearables for atrial fibrillation detection stratified by ageOA北大核心
Health behavior outcomes in stroke survivors prescribed wearables for atrial fibrillation detection stratified by age
BACKGROUND Smartwatches have become readily accessible tools for detecting atrial fibrillation(AF).There remains lim-ited data on how they affect psychosocial outcomes and engagement in older adults.We examine the health behavior outcomes of stroke survivors prescribed smartwatches for AF detection stratified by age. METHODS We analyzed data from the Pulsewatch study,a randomized controlled trial that enrolled patients(≥50 years)with a history of stroke or transient ischemic attack and CHA2DS2-VASc≥2.Intervention participants were equipped with a car-diac patch monitor and a smartwatch-app dyad,while control participants wore the cardiac patch monitor for up to 44 days.We evaluated health behavior parameters using standardized tools,including the Consumer Health Activation Index,the General-ized Anxiety Disorder questionnaire,the 12-Item Short Form Health Survey,and wear time of participants categorized into three age groups:Group 1(ages 50-60),Group 2(ages 61-69),and Group 3(ages 70-87).We performed statistical analysis using a mixed-effects repeated measures linear regression model to examine differences amongst age groups. RESULTS Comparative analysis between Groups 1,2 and 3 revealed no significant differences in anxiety,patient activation,perception of physical health and wear time.The use of smartwatch technology was associated with a decrease in perception of mental health for Group 2 compared to Group 1(β =-3.29,P = 0.046). CONCLUSION Stroke survivors demonstrated a willingness to use smartwatches for AF monitoring.Importantly,among these study participants,the majority did not experience negative health behavior outcomes or decreased engagement as age in-creased.
Joanne Mathew;Kamran Noorishirazi;Irina Radu;Jane Saczynski;David D.McManus;Khanh-Van Tran;Jordy Mehawej;Ziyue Wang;Taylor Orwig;Eric Ding;Andreas Fi-lippaios;Syed Naeem;Edith Mensah Otabil;Alex Hamel
Division of Cardiovascular Medicine,Department of Medicine,University of Massachusetts Chan Medical School,Lake Avenue North,Worcester,USA||Department of Internal Medicine,Central Michigan University,Mount Pleasant,USADivision of Cardiovascular Medicine,Department of Medicine,University of Massachusetts Chan Medical School,Lake Avenue North,Worcester,USADepartment of Pharmacy and Health Systems Sciences,School of Pharmacy,Northeastern University,Boston,USADivision of Cardiovascular Medicine,Department of Medicine,University of Massachusetts Chan Medical School,Lake Avenue North,Worcester,USA||Department of Population and Quantitative Health Sciences,University of Massachusetts Chan Medical School,Lake Avenue North,Worcester,USA
《老年心脏病学杂志(英文版)》 2024 (003)
323-330 / 8
The Pulsewatch Study is funded by R01HL137734 from the National Heart,Lung,and Blood Institute.Dr.Ding's time is supported by F30HL149335 from the National Heart,Lung,and Blood Institute.Dr.Mehawej's time is supported by NIH grant 2T32HL 120823.Dr.Tran's time is supported by K23HL16 1432 from the National Heart,Lung,and Blood In-stitute.Dr.Chon's time was supported by R01 HL137 734 and Dr McManus's time is supported by R01HL126911,R01HL137734,R01HL137794,R01HL135219,R01HL136660,U54HL143541,and 1U01HL146382 from the National Heart,Lung,and Blood Institute.
评论